Takeda Pharmaceutical (TAK) said Tuesday it signed a master agreement with Astellas Pharma and Sumitomo Mitsui Banking to establish a joint venture company, Ciconia Bioventures.
Ciconia will cover the entire process from early drug discovery research to the formation of biotech startups with the aim of turning innovative technologies originating in Japan into clinical applications, the company said.
"Ciconia will evaluate early development stage seeds, establish its own company based on the selected seeds, raise funds worldwide and pursue global product development," Ciconia founder and Chief Executive Toshio Fujimoto said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments